The Good Life

The top 4 reasons why businesses are rewarding employees by choosing Pearland

Don't forget about quality of life when choosing where to put your headquarters. Photo courtesy of PEDC

Employees consistently say that quality of life is an important factor when choosing which corporations to align themselves with, and more and more companies are discovering the appeal of Pearland, in Lower Kirby.

Global facilities such as Lonza have chosen the area based on its many attractive factors, adding another incentive when recruiting.

Here's a look at what Pearland has to offer:

Education
The school districts serving the Pearland area, such as Pearland ISD and Alvin ISD, are all highly rated, plus it's home to the University of Houston – Clear Lake Pearland campus.

Eight bachelor's degree programs are offered, along with six programs to obtain a graduate or professional degree.

Recreation
Got a little slugger or aspiring quarterback in the family? Pearland boasts both a champion Little League World Series team and state champions in high school football.

Organized sports aside, families will soon be able to enjoy the 21-mile Clear Creek Trail, which is currently in development and will span the entire length of the Pearland community when finished.

Developments in recent years have added a variety of retail and restaurant options, with the largest being the Pearland Town Center.

Housing
Texas in general is experiencing a housing surge, but Pearland is especially booming. More than 10,000 single-family homes have been constructed over the past 10 years, with no signs of the growth slowing.

Plus, employees moving from dense urban areas are delighted to discover the Lone Star State's wide-open spaces.

Healthcare
Pearland is a community that values healthcare — the 77584 ZIP code is home to more Texas Medical Center employees than any other in the region.

In fact, more than 13 percent of Pearland residents work in healthcare. They have many opportunities from which to choose, as many entities have opened new campuses in the past several years, including Memorial Hermann, HCA Healthcare, and Kelsey-Seybold.

Explore more about Pearland and what makes it great for businesses here.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News